NO303265B1 - Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom - Google Patents

Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom

Info

Publication number
NO303265B1
NO303265B1 NO931317A NO931317A NO303265B1 NO 303265 B1 NO303265 B1 NO 303265B1 NO 931317 A NO931317 A NO 931317A NO 931317 A NO931317 A NO 931317A NO 303265 B1 NO303265 B1 NO 303265B1
Authority
NO
Norway
Prior art keywords
xanthine derivatives
group
parkinson
disease
preparation
Prior art date
Application number
NO931317A
Other languages
English (en)
Norwegian (no)
Other versions
NO931317L (no
NO931317D0 (no
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Shunji Ichikawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO931317D0 publication Critical patent/NO931317D0/no
Publication of NO931317L publication Critical patent/NO931317L/no
Publication of NO303265B1 publication Critical patent/NO303265B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO931317A 1992-04-08 1993-04-06 Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom NO303265B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (3)

Publication Number Publication Date
NO931317D0 NO931317D0 (no) 1993-04-06
NO931317L NO931317L (no) 1993-10-11
NO303265B1 true NO303265B1 (no) 1998-06-22

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931317A NO303265B1 (no) 1992-04-08 1993-04-06 Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom

Country Status (11)

Country Link
EP (1) EP0565377B1 (fr)
JP (1) JP2613352B2 (fr)
AT (1) ATE161723T1 (fr)
BR (1) BR1100636A (fr)
CA (1) CA2093403C (fr)
DE (1) DE69316067T2 (fr)
DK (1) DK0565377T3 (fr)
ES (1) ES2112386T3 (fr)
GR (1) GR3026233T3 (fr)
HK (1) HK1001835A1 (fr)
NO (1) NO303265B1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106771C (fr) * 1992-02-19 2004-11-02 Yukio Ishida Riz a forte teneur d'eau absorbee, methode de production et application
CA2116967C (fr) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepresseurs
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
DE69526822T2 (de) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Xanthin-derivate
DE69731556T2 (de) * 1996-08-07 2005-10-27 Kyowa Hakko Kogyo Co., Ltd. Fettemulsion, die ein xanthinderivat enthält
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
EP1440072A4 (fr) 2001-10-30 2005-02-02 Conforma Therapeutic Corp Analogues de purine presentant une activite inhibitrice de hsp90
WO2004096228A1 (fr) 2003-04-25 2004-11-11 Novacardia, Inc. Methode pour ameliorer la diurese chez des personnes a fonction renale alteree
US7148228B2 (en) 2003-09-18 2006-12-12 Conforma Therapeutics Corporation Pyrazolopyrimidines and related analogs as HSP90-inhibitors
WO2005072739A1 (fr) 2004-01-28 2005-08-11 Kyowa Hakko Kogyo Co., Ltd. Medicament contre la migraine
KR20080004550A (ko) * 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
CA2608111A1 (fr) * 2005-04-22 2006-11-02 Novacardia, Inc. Production d'emulsions de compositions pharmaceutiques
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (fr) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. Dérivés de styryl xanthine substitués en position 8 et leurs utilisations
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112409360B (zh) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 杂芳基乙烯基黄嘌呤衍生物及其用途
US20230017597A1 (en) * 2019-11-11 2023-01-19 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2059577B1 (fr) * 1969-07-30 1973-08-10 Parke Davis & Co
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
ATE176470T1 (de) * 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate

Also Published As

Publication number Publication date
NO931317L (no) 1993-10-11
DE69316067D1 (de) 1998-02-12
DE69316067T2 (de) 1998-07-02
ES2112386T3 (es) 1998-04-01
GR3026233T3 (en) 1998-05-29
EP0565377B1 (fr) 1998-01-07
CA2093403C (fr) 1999-08-10
ATE161723T1 (de) 1998-01-15
JPH0616559A (ja) 1994-01-25
EP0565377A1 (fr) 1993-10-13
DK0565377T3 (da) 1998-03-16
CA2093403A1 (fr) 1993-10-09
NO931317D0 (no) 1993-04-06
HK1001835A1 (en) 1998-07-10
BR1100636A (pt) 2000-04-18
JP2613352B2 (ja) 1997-05-28

Similar Documents

Publication Publication Date Title
NO303265B1 (no) Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom
NO933452L (no) Et terapeutisk middel for Parkinson's sykdom
HUT68856A (en) Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
ATE232531T1 (de) Heterobizyklische derivate
DE10199003I1 (de) Substituierte Thiazolidinionderivate
ATE118487T1 (de) Thiazolidinedionederivate.
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
KR900001701A (ko) 이미다조피라졸 유도체의 진통제 및 항염제로서의 용도
KR940003920A (ko) 테트라히드로나프탈렌 유도체, 이것의 제법 및 이것의 치료에의 이용
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.
KR910006251A (ko) 3-이속사졸론 유도체, 그의 제조방법 및 그의 치료적 용도
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees